DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device company have returned +3.6% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Instruments industry, to which DexCom belongs, has lost 0.3% over this period. Now the key question is: Where could the stock be headed in the near term?Although media re ...

股价表现 - DexCom (DXCM) 最近的股价为 $136.65，较前一天收盘价下跌了 -0.94% [1] 财务表现 - DexCom 公司预计在即将发布的财报中将发布每股收益为 $0.27，同比增长58.82%，预计营收为 $911.2 亿美元，同比增长22.89% [3] 股票评级 - DexCom 目前的 Zacks Rank 为 2 (买入)，过去一个月的 Zacks Consensus EPS 估计保持稳定 [7] 估值比较 - DexCom 目前的 Forward P/E ratio 为 78.38，较同行业平均值 25.08 偏高 [8]

DexCom公司背景 - DexCom是一家领先的连续血糖监测系统制造商，主要为1型糖尿病患者提供服务，占糖尿病人口的5%[1] - DexCom计划推出Stelo，这是一款针对2型糖尿病患者的CGM系统，不需要进行指尖刺痛，直接与Abbott Lab的Freestyle Libre竞争[2] - DexCom是医疗领域的一家领先医疗器械公司，专门专注于连续血糖监测系统。CGM系统使用小型传感器插入皮肤，在一天中提供稳定的血糖读数。公司与Abbott Laboratories和Medtronic plc竞争[3] 糖尿病相关信息 - 糖尿病是一个不断增长的流行病，全球有近3千万糖尿病患者，预计到2030年可能增长到5千万。全球估计到2045年将有7.8亿糖尿病患者，国家25%的医疗支出用于糖尿病患者[5] DexCom财务表现 - DexCom报告2023年第四季度每股收益为50美分，超过43美分的分析师一致预期7美分。营收同比增长27%至10.3亿美元，超过10.2亿美元的一致预期。美国和国际营收同比增长27%。GAAP运营收入为2.169亿美元，占营收的21%。非GAAP运营收入为2.427亿美元，占营收的23.5%[9] - DexCom提供2024年全年营收预计为41.5亿至43.5亿美元，高于43.3亿美元的一致预期。非GAAP毛利率将在63%至64%之间。非GAAP运营利润率预计约为20%。调整后的EBITDA利润率预计约为29%[10] DexCom未来展望 - DexCom首席执行官Ken Sayer表示，“2023年对Dexcom来说是一个不可思议的一年，扩大了访问范围，创下了新客户启动的记录，并在全球推出Dexcom G7的势头增长。” Sayer总结道，“我们期待在2024年再次取得辉煌成就，努力改善全球更多人的健康，使用Dexcom CGM技术”[11]

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this medical device company have returned +13.9%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Medical - Instruments industry, which DexCom falls in, has gained 3.9%. The key question now is: What could be the stock's future direction?While media ...

DexCom (DXCM) closed the most recent trading day at $134.17, moving -0.41% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.57%. On the other hand, the Dow registered a gain of 0.83%, and the technology-centric Nasdaq increased by 0.39%.Heading into today, shares of the medical device company had gained 15.1% over the past month, outpacing the Medical sector's gain of 0.13% and the S&P 500's gain of 2.97% in that time.The investment community will be closely ...

经纪公司分析师推荐 - 投资者常常依赖分析师推荐来决定是否买入、卖出或持有股票，但研究表明经纪公司的推荐并不总是能够指导投资者选择潜在价格增长最大的股票[4] - 经纪公司的分析师往往会对所覆盖的股票给予强烈的正面偏见，通常会给出五个“强烈买入”推荐，而只有一个“强烈卖出”推荐[5] Zacks Rank评级工具 - Zacks Rank是一种有效的股票评级工具，将股票分为五组，从Zacks Rank 1（强烈买入）到Zacks Rank 5（强烈卖出），是预测股票未来价格表现的有效指标[7]

股价表现 - DexCom (DXCM) 最近的股价为 $133.04，较前一交易日收盘价下跌了 -1.63% [1] - DexCom 过去一个月的股价上涨了 12.27%，超过了医疗行业的涨幅 3.03% 和标普500指数的涨幅 2.7% [2] 财务预期 - DexCom 预计将发布每股收益为 $0.27，同比增长 58.82%，预计营收为 $909.9 亿美元，同比增长 22.71% [3] - DXCM 全年的 Zacks 一致预期为每股收益 $1.74 和营收 $43.1 亿美元，同比增长分别为 +14.47% 和 +18.98% [4] 分析评级 - DexCom 目前的 Zacks Rank 为 3 (Hold)，过去30天内，一致预期的每股收益增长了 1.8% [7] 行业比较 - DexCom 目前的前瞻市盈率为 77.62，高于行业平均值 28.35 [8] - DXCM 的 PEG 比率为 2.35，医疗仪器行业的平均 PEG 比率为 2.35 [9] - 医疗仪器行业在医疗领域中排名第70，位于所有250多个行业的前28% [10] - Zacks Industry Rank 表明，评级较高的行业胜过评级较低的行业，前50%的行业胜过后50%的行业2比1 [11] 建议 - 使用 Zacks.com 可以追踪所有这些影响股价的指标，在未来的交易中保持关注 [12]

A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can assist people in staying on top of chronic conditions, including hypertension and diabetes.This hasn't exactly been a hot place to invest in, however. Since 2021, the iShares US Medical Devices ETF has risen by just 6%, while the S&P 500 has achieved gains in excess of 36%. But as many investors have been overlooki ...

DexCom公司新产品Stelo获得FDA批准 - DexCom公司股价本周上涨近10%[1] - Stelo是一款小型可穿戴传感器，适用于成年糖尿病患者[3] - FDA已批准Stelo供非糖尿病患者使用，扩大了目标患者群[3] Stelo无需处方即可购买 - 预计将增加产品的需求，扩大潜在市场[4] DexCom的OTC传感器Stelo在减肥治疗期间有应用 - 可帮助患者跟踪健康状况，即使没有保险覆盖[6] Stelo有望成为DexCom未来组合中的关键产品 - 得到强大的基本面支持[8]

DexCom公司 - DexCom (DXCM)是医疗股中表现出色的公司[1] - DexCom目前在Zacks Sector Rank中排名第4[2] - DexCom目前的Zacks Rank为2（买入）[3] - 过去三个月，DXCM全年盈利的Zacks Consensus Estimate上调了2.6%[4] - DXCM今年迄今涨幅约为7.8%，高于医疗股平均涨幅7.2%[5] - DexCom属于医疗-仪器行业，今年迄今涨幅略低于行业平均值8.4%[8] Ambrx Biopharma Inc. - Ambrx Biopharma Inc.（AMAM）今年迄今涨幅为96.6%，表现优异[6] - Ambrx Biopharma Inc.的当前年度一致EPS预估增加了1%[7] - Ambrx Biopharma Inc.属于医疗-生物医学和遗传学行业，行业今年迄今上涨了2.4%[9] - DexCom和Ambrx Biopharma Inc.可能会继续表现强劲，值得关注[10]